Source:http://linkedlifedata.com/resource/pubmed/id/20113211
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2010-3-11
|
| pubmed:abstractText |
Herpes zoster or shingles is a condition with the potential to result in severe debilitation. It affects approximately 10 - 30% of the population. Until recently there were only treatments to shorten the duration and lessen the symptoms of herpes zoster, but no practical or approved method of prevention for susceptible immunocompetent adults. The live attenuated zoster vaccine (Zostavax, Merck & Co., Inc.) is effective in preventing shingles in individuals 60 years of age and older and recommended by the Center for Disease Control's (CDC) Advisory Committee for Immunization Practices (ACIP).
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
1744-7682
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
631-8
|
| pubmed:meshHeading | |
| pubmed:year |
2010
|
| pubmed:articleTitle |
Shingles vaccine.
|
| pubmed:affiliation |
Center for Clinical Studies, 451 North Texas Avenue, Webster, Texas 77598, USA. bwillison@ccstexas.com
|
| pubmed:publicationType |
Journal Article,
Review
|